NCT06138990 Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
| NCT ID | NCT06138990 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | ETH Zurich |
| Condition | AML, Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 88 participants |
| Start Date | 2024-09-02 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 88 participants in total. It began in 2024-09-02 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
Eligibility Criteria
Inclusion criteria * Patient with refractory or relapsed AML according to ELN2022 criteria. * Age 18-70 years. * Considered to be eligible for intensive chemotherapy. * Written informed consent. Exclusion criteria * Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomonic variant fusion genes/chromosome translocations. * Blast crisis after chronic myeloid leukemia (CML). * Considered not eligible for intensive chemotherapy. * Condition of the patient does not allow to wait for PCY results (patient requires immediate treatment). * PCY not working / patient sample did not pass the QC steps of PCY. * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the principal investigator may interfere with the project or affect patient compliance. * Legal incompetence or Subjects lacking capacity to provide informed consent. * Participation in a clinical trial with an investigational drug within the
Frequently Asked Questions
Who can join the NCT06138990 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying AML, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06138990 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06138990 currently recruiting?
Yes, NCT06138990 is actively recruiting participants. Visit ClinicalTrials.gov or contact ETH Zurich to inquire about joining.
Where is the NCT06138990 trial being conducted?
This trial is being conducted at Bern, Switzerland, Zurich, Switzerland.
Who is sponsoring the NCT06138990 clinical trial?
NCT06138990 is sponsored by ETH Zurich. The trial plans to enroll 88 participants.